# Bivariate joint modelling for mixed continuous and binary responses in the presence of non-monotone, non-ignorable missingness: The case of prostate cancer

Madiha Liaqat, Shahid Kamal, Florian Fischer

# Madiha Liaqat

College of Statistical and Actuarial Sciences (CSAS), University of the Punjab, Lahore, Pakistan <u>madiha.phd.stat@pu.edu.pk</u>

# Prof. Dr. Shahid Kamal

College of Statistical and Actuarial Sciences (CSAS), University of the Punjab, Lahore, Pakistan <u>kamal0shahid@gmail.com</u>

# Dr. Florian Fischer [Corresponding author]

Institute of Public Health, Charité – Universitätsmedizin Berlin, Berlin, Germany florian.fischer1@charite.de

## **Corresponding author:**

Dr. Florian Fischer Charité – Universitätsmedizin Berlin Institute of Public Health Charitéplatz 1 10117 Berlin Germany florian.fischer1@charite.de

# 1 Abstract

Joint modelling for mixed longitudinal responses has played a prominent part in disease decision-2 making. It is based on a joint strategy of estimating joint likelihood with shared random effects. 3 Non-ignorable missingness in outcomes increases complexity in joint model; a shared parameter 4 model is proposed to incorporate non-ignorable missing data for joint modelling of longitudinal 5 responses and missing data mechanism. Parameters are estimated under the Bayesian paradigm 6 and implemented via Markov chain Monte Carlo (MCMC) methods with Gibbs sampler. To 7 demonstrate the effectiveness of the proposed method, the joint model is applied to analyze a 8 9 prostate cancer dataset. The objective is to assess whether there is an association between two mixed longitudinal biomarkers, which could have important implications for understanding 10 disease progression and guiding treatment decisions. The dataset contains non-monotone 11 12 missingness pattern. To evaluate the performance and robustness of the proposed joint model, simulation studies are conducted. 13

14

15 *Keywords:* missing data, missingness, oncology, prostate

# 16 1. Introduction

Longitudinal studies have a wide range of applications in medicine, where measurements are repeatedly observed for individuals over time. These measurements are correlated even for different types of responses and collected for the same individuals. For example, in oncology research, more than one biomarker of mixed types is measured repeatedly over time for the same patient. These biomarkers are inherently associated – and this association is accounted for valid conclusions. Simultaneous modelling of mixed biomarkers is an optimal approach to account for correlation among multiple biomarkers [1].

24 Missing data is an unavoidable issue in longitudinal studies because patients may not come for a pre-specified follow-up visit at a particular time point for many reasons. In this regard, missingness 25 exists in collected data and creates hindrances to extracting inference without making assumptions 26 about the missingness mechanism. According to Rubin [2], missing completely at random 27 (MCAR) and missing at random (MAR) mechanisms being not dependent upon unobserved 28 measurements are ignorable. Not missing at random (NMAR) mechanism may depend upon both 29 observed and unobserved responses and is considered non-ignorable. Non-ignorable missingness 30 mechanism is considered in data analysis with longitudinal measurements to get unbiased 31 32 estimates.

In literature, selection models, pattern-mixture models (PMMs), and shared parameter models (SPMs) are mostly applied to tackle non-ignorable missing data. These models use different factorizations for missingness and measured processes to jointly model longitudinal responses incorporating missingness. The SPM approach is widely applied to model MAR data in longitudinal responses. Still, there exists a gap to employ SPM for NMAR. Non-ignorable missing data is addressed by employing logistic or probit models, which are specifically designed to handle

situations where the missing data mechanism is influenced by unobserved variables or responses,
resulting in NMAR mechanisms. By integrating the logistic or probit model into the analysis,
researchers can effectively mitigate potential biases caused by non-ignorable missing data that
consequently makes precise inferences based on the available data. Logistic and probit models
provide valuable insights into the underlying patterns of missingness, contributing to obtaining
reliable results in longitudinal studies and other scenarios where missing data is common.

Joint modelling terms are applied to simultaneously analyzed more than one outcome. Many 45 methods have been proposed to jointly analyze single or multivariate longitudinal measurements 46 47 alongside event time data in recent years [3,4]. Another joint modelling term is used to simultaneously analyze more than one longitudinal outcome possibly of different types using 48 random effects, marginal or conditional models [5,6]. Catalano and Ryan [7] analyzed toxicity 49 data proposing bivariate latent variable models to account for the relationship between fetal weight 50 and malformation in live fetuses. Leon and Carriere [8] studied one longitudinal and one binary 51 response to assess maternal smoking's effect on the respiratory illness of children. Liu et al. [9] 52 formulated a joint model to handle longitudinal binary and continuous responses by incorporating 53 an ignorable missing data mechanism. Li et al. [10] applied joint modelling for continuous, binary, 54 and ordinal responses under the Bayesian framework, while Kürüm et al. [11] proposed a joint 55 56 model to analyze binary and continuous responses under frequentist statistics.

Under the umbrella of non-ignorable missing data (NMAR) fall both non-monotone and monotone missingness patterns, which in turn provide incomplete observations. Intermittent missingness comes under non-monotone missingness pattern, where an individual misses any visit during the follow-up time, and returns to show up for subsequent visits. The monotone missingness pattern usually refers to informative drop-out, where an individual leaves the study before completion and

62 never comes back to complete follow-up time. Stubbendick and Ibrahim [12] used a likelihood63 based approach to incorporate non-monotone NMAR by proposing a joint likelihood of outcome
64 and missing data indicators. Hogan et al. [13] worked on monotone missingness in longitudinal
65 data. Gaskins et al. [14] worked on non-ignorable drop-out mixed longitudinal responses using
66 PMM under joint modelling methodology.

In this article, a joint model is proposed for longitudinal continuous-binary biomarkers using a conditional modelling approach, and two shared parameter models are proposed for non-ignorable missingness under the conditional model. For estimating the model's parameters different approaches are employed: likelihood-based approach, linear programming technique, and Bayesian approach. We work under the Bayesian framework to obtain parameter estimates.

The article presents a robust statistical approach to analyze longitudinal mixed-effects biomarker measurements, accounting for non-monotone, non-ignorable missingness in the context of prostate cancer research. By utilizing joint modelling techniques and considering the missingness mechanisms, the researchers aim to obtain more reliable and meaningful results from their data analysis.

77

### 78 2. Motivation: Prostate cancer dataset

This research is motivated by a comprehensive dataset obtained from prostate cancer patients who underwent external beam radiotherapy (EBRT), Androgen deprivation therapy (ADT), and a combination of ADT along with other therapies. This dataset spans from 2012 to 2019 and includes information collected during up to 5 follow-up visits after treatment. The data was sourced from Mayo hospital, a renowned referral hospital in Pakistan. Data was received in 2021 by the authors of this study. The authors had no access to information that could identify individual participants.

The evaluation of patients took place from the pre-treatment phase to the post-treatment follow-85 up. During the pre-treatment phase, demographic characteristics and medical history of the patients 86 were recorded. We specifically focused on patients' age, body mass index (BMI), and Gleason 87 score as baseline predictors for our study. Blood tests were also conducted to measure prostate-88 specific antigen (PSA), alkaline phosphatase (ALT), platelets, and bilirubin. These biomarkers 89 were tracked after treatment at each follow-up visit, with PSA and ALP values considered as 90 indicators of prostate cancer progression after treatment, and endogenous platelets and bilirubin as 91 time-dependent covariates. Our study included a total of 1,504 patients diagnosed with prostate 92 93 cancer, out of which 1,026 received ADT and combination therapies as part of their treatment.

94

#### 95 3. Model specification

### 96 3.1 Model for longitudinal measurements

Data analysis is described by the joint model specification; sub-models illustrate such mixed types
of complex data modelling. The first sub-model assumes to follow linear mixed-effects model
specified for continuous longitudinal biomarker. Binary longitudinal response is assumed to follow
mixed-effects logistic regression model.

101 Let  $Y_{ij}$  be the continuous longitudinal outcome for  $i^{th}$  individual i = 1,2,3,...,n at time  $t_{ij}$ 102  $j = 1,2,3,...,m^y$ , assume linear mixed effects model as

$$Y_{ij} = x_{ij}^{y'} \alpha_1 + w_{ij}^{y'} u_{1i} + \varepsilon_{ij}$$
<sup>(1)</sup>

104 where,  $\alpha_1$  is a  $p^y$  dimensional vector of fixed effects regression coefficients,  $x_{ij}^y$  vector of 105 covariates.  $w_{ij}^y$  is  $q^y$  dimensional vector of random effects,  $u_{1i}$  is a vector of random effects, that 106 is independently and identically distributed as multivariate normal with mean vector 0 and 107 covariance matrix D.  $\varepsilon_{ij} \sim N(0, \sigma_{\varepsilon}^2)$  is the random error term.

Let,  $Z_{ij}$  be the binary repeated measurements observe for  $i^{th}$  individual, i = 1,2,3,...,n at time  $s_{ij}$ . Where  $s_{ij} = t_{ij}$ ,  $j = 1,2,3,...,m^z$ , binary response  $Z_{ij}$  assumes to follow logistic mixed effects model that is given by

111 
$$Z_{ij}|u_{2i}\sim Ber(\lambda_{ij}),$$

112 
$$logit(\lambda_{ij}) = x_{ij}^{z'} \alpha_2 + w_{ij}^{z'} u_{2i} + Y_j Y_{ij}, \qquad (2)$$

113

114 where,  $\alpha_2$  is a  $p^z$  dimensional vector of fixed effects regression coefficients,  $x_{ij}^z$  vector of 115 covariates.  $w_{ij}^z$  is  $q^y$  dimensional vector of random effects,  $u_{2i} \sim MVN(0, D)$  is a vector of random 116 effects, with the addition of associated parameter  $\Upsilon_j$  to measure the effect of response  $Y_{ij}$  at time 117  $t_{ij}$  on response  $Z_{ij}$  at the same time  $s_{ij}$ .

118

# 119 3.2 Missing data mechanism and shared parameter model

Longitudinal data are not fully observed which leads to incomplete measurements. The most important consideration is to specify an appropriate missing data mechanism based on assumptions related to unobserved and observed data. Little and Schluchter [15] as well as Fitzmaurice and Laird [16] applied general location model described by Olkin and Tate [17] assuming the ignorability assumption. This assumption leads to the usage of observed responses only without considering a model for missingness mechanism. Usually, the expectation-maximization (EM) algorithm is employed for parameter estimation.

In this study, we examine two distinct missingness mechanisms to account for the presence of two
 different missingness patterns in longitudinal outcomes, two SPM are specified for missingness
 mechanisms.

130 Let  $R_i = (R_{i1}, R_{i2}, R_{i3}, \dots, R_{in})'$  be the vector of response indicators, if  $Y_{ij}$  observed  $R_{ij} = 1$ , and  $R_{ij}$ 

131 = 0 for missing  $Y_{ij}$ . In this paper, a SPM based on non-ignorable missigness mechanisms for  $Y_i$ 

and  $Z_i$  consider, assuming logistic mixed effects regression models for  $R_{ij}^{y}$  and  $R_{ij}^{Z}$  responses.

133 Let  $R_{ij}^{y}$  be the missingness indicator for continuous response at time  $t_{ij}$ , such that  $R_{ij}^{y} = 1$  if  $Y_{ij}$  is

134 not fully observed, the model for  $R_{ij}^{y}$  is given by

135 
$$R_{ij}^{\gamma}|u_{1i} \sim Ber(\lambda_{ij}^{R^{\gamma}}),$$

136 
$$logit(\lambda_{ij}^{R^{y}}) = \psi_{ij}^{y'} \Phi_{1} + \pi^{y'} u_{1i},$$
 (3)

137

138 Let  $R_{ij}^z$  be the missingness indicator for continuous response at time  $s_{ij}$ , such that  $R_{ij}^z = 1$  if  $Z_{ij}$  is 139 not fully observed, the model for  $R_{ij}^z$  is given by

140 
$$R_{ij}^{z}|u_{2i} \sim Ber(\lambda_{ii}^{R^{z}}),$$

141 
$$logit(\lambda_{ij}^{R^{z}}) = \psi_{ij}^{z'} \Phi_{2} + \pi^{z'} u_{2i} + \kappa_{j} R_{ij}^{y}, \qquad (4)$$

142 To formulate joint distribution of responses given the random effects, let  $Y_{ij}$  and  $Z_{ij}$  are partitioned 143 into  $Y_{ij} = (Y_{ij}^{obs}, Y_{ij}^{mis})$  and  $Z_{ij} = (Z_{ij}^{obs}, Z_{ij}^{mis})$ , respectively.

144 Joint model given the random effects is given as

145 
$$f(Y_{ij}^{obs}, Z_{ij}^{obs}, Y_{ij}^{mis}, Z_{ij}^{mis} | u_{1i}, u_{2i}) = f(Y_{ij}, Z_{ij}, R_{ij}^{v}, R_{ij}^{z} | u_{1i}, u_{2i})$$

146 
$$f(Y_{ij}, Z_{ij}, R_{ij}^{y}, R_{ij}^{z} | u_{1i}, u_{2i}) = f(Z_{ij} | Y_{ij}, R_{ij}^{y}, R_{ij}^{z}, u_{1i}, u_{2i}) \times f(Y_{ij} | R_{ij}^{y}, R_{ij}^{z}, u_{1i}) \times f(R_{ij}^{z} | R_{ij}^{y}, u_{1i}, u_{2i}) \times f(R_{ij}^{y} | u_{1i}, u_{2i})$$

147 
$$= f(Z_{ij} | Y_{ij}, R_{ij}^z, u_{2i}) \times f(Y_{ij} | R_{ij}^y, u_{1i}) \times f(R_{ij}^z | R_{ij}^y, u_{2i}) \times f(R_{ij}^y | u_{1i})$$

148 
$$= f(Z_{ij} | Y_{ij}, u_{2i}) \times f(Y_{ij} | u_{1i}) \times f(R_{ij}^z | R_{ij}^y, u_{2i}) \times f(R_{ij}^y | u_{1i}).$$
(5)

149 Joint probability distribution function is formulated further as

150 
$$f(Y_{ij}, Z_{ij}, R_{ij}^{y}, R_{ij}^{z}) = \int_{u_{1i}} \int_{u_{2i}} f(Y_{ij}, Z_{ij}, R_{ij}^{y}, R_{ij}^{z} | u_{1i}, u_{2i}) h(u_{1i}, u_{2i}) du_{1i} du_{2i}$$

151 
$$= \int_{u_{1i}} \int_{u_{2i}} \prod_{j=1}^{m^{y}} f(Y_{ij}|u_{1i}) \prod_{j=1}^{m^{z}} f(Z_{ij}|u_{2i},Y_{ij}) \times \prod_{j=1}^{m^{y}} f(R_{ij}^{y}|u_{1i}) \prod_{j=1}^{m^{z}} f(R_{ij}^{z}|u_{2i},Y_{ij}) du_{1i} du_{2i}.$$
152 (6)

#### **3.3 Prior distributions and hierarchical model**

The unknown parameters of the proposed model are estimated by employing the Bayesian framework using Markov chain Monte Carlo (MCMC) techniques [18]. MCMC has an advantage over conventional methods, with MCMC conditional distribution of each parameter given others is easily specifying. Priors are chosen to carry out Bayesian inference for unknown parameters, let  $\emptyset = \{\alpha_1, \alpha_2, \sigma^2, D_1, D_2, \Phi_1, \Phi_2, \pi^y, \pi^z, \Upsilon_k, \kappa_k\}$  be the unknown parameters' vector where k = 1, 2, 3, ..., k $m^{y}$  and  $l = 1, 2, 3, ..., m^{z}$ . We specify proper prior for each set of unknown parameters: Gaussian distribution for the fixed effects, and Inverse Gamma distribution for random effects. Different levels of variances for each distribution are tried out to make robust choice of fixed effects estimates. Independent prior distributions for unknown parameters are chosen by assigning hyperparameters that lead to low-informative prior distributions. 

- $\alpha_1 \sim N'_{p1}(\mu_{\alpha_1}, \sum_{\alpha_1}),$
- $\sigma^2 \sim I\Gamma(a_{\sigma^2}, b_{\sigma^2}),$
- $\alpha_2 \sim N'_{p2}(\mu_{\alpha_2}, \sum_{\alpha_2}),$
- $D_1 \sim IWishart(\psi_{D_1}, v_{D_1}),$
- $D_2 \sim IWishart(\psi_{D_2}, v_{D_2}),$
- $\Phi_1 \sim N'_{p_R^{\nu}}(\mu_{\Phi_1}, \sum_{\Phi_1}),$
- $\Phi_2 \sim N'_{P_R^z}(\mu_{\Phi_2}, \sum_{\Phi_2}),$
- $\pi^{\mathcal{Y}} \sim N'_{q^{\mathcal{Y}}}(\mu_{\pi^{\mathcal{Y}}}, \sum_{\pi^{\mathcal{Y}}}),$
- $\pi^{z} \sim N'_{q^{z}}(\mu_{\pi^{z}}, \Sigma_{\pi^{z}}),$

173 
$$r \sim \Gamma(a_r, b_r)$$

174 
$$\gamma_{j} \sim N(\mu_{\gamma_{j}}, \sigma_{\gamma_{j}}^{2}), j = 1, 2, 3, ..., m^{3}$$

175 
$$\kappa_{i} \sim N(\mu_{\kappa_{i}}, \sigma_{\kappa_{i}}^{2}), j = 1, 2, 3, ..., m^{z},$$
 (7)

176

where  $I\Gamma(a,b)$  and  $\Gamma(a,b)$  denote inverse gamma distribution and gamma distribution with shape 177 parameter a and scale parameter b. IWishart ( $\psi$ , v) represents the inverse Wishart distribution 178 with scale and matrix parameters v and  $\psi$ , respectively. N( $\mu$ ,  $\Sigma$ ) denotes a normal distribution with 179 mean vector  $\mu$  and covariance matrix  $\Sigma$ . 180

#### The joint posterior density is formulated as 181

$$\Theta(\emptyset, u_{1}, u_{2}, Y_{ij}^{mis}, Z_{ij}^{mis} | Y_{ij}^{obs}, Z_{ij}^{obs}, R_{ij}^{v}, R_{ij}^{z}) \propto \prod_{i=1}^{n} \prod_{j=1}^{m^{v}} \mathbb{P}(Y_{ij}; x_{ij}^{y'} \alpha_{1} + w_{ij}^{y'} u_{1i}, \sigma_{\varepsilon}^{2}) \times (\lambda_{ij}^{R^{v}})^{R_{ij}^{v}} (1 - \lambda_{ij}^{R^{v}})^{R_{ij}^{v}} \\
\times \prod_{i=1}^{n} \prod_{k=1}^{m^{z}} (\lambda_{ij})^{z_{ik}} (1 - \lambda_{ij})^{z_{ik}} \times (\lambda_{ij}^{R^{z}})^{R_{ik}^{z}} (1 - \lambda_{ij}^{R^{z}})^{R_{ik}^{z}} \times \Theta(\emptyset),$$
183
$$(8)$$

103

184

where,  $\Theta(\emptyset)$  is the joint prior distribution of unknown parameters. 185

Samples are drawn iteratively from conditional posterior distributions derived from (8) using 186 Gibbs sampler, the full conditional distributions for parameters are given by 187

188 
$$\alpha|_{\bigcup(-\alpha)}, Y_{ij}^{obs}, Z_{ij}^{obs}, R_{ij}^{y}, R_{ij}^{z} \sim N_{p^{\gamma}}(\sum_{\alpha \mid \cdots} (\prod_{i=1}^{n} x_{i}^{y^{\prime}} \frac{Y_{i} - w_{i}^{y^{\prime}} a_{1i}}{\sigma_{\varepsilon}^{2}}), \sum_{\alpha \mid \cdots})$$
(9)

Where  $\sum_{\alpha \mid \dots} = \left(\frac{\sum_{i=1}^{n} x_i^{y'} x_i^{y}}{\sigma_{\varepsilon}^2} + \sum_{\alpha_1}^{-1}\right)^{-1}$ . 189

190 
$$\sigma_{\varepsilon}^{2}|U_{(-\sigma_{\varepsilon}^{2})},Y_{ij}^{obs},Z_{ij}^{obs},R_{ij}^{y},R_{ij}^{z}\sim \Gamma(\frac{m_{y}n}{2}+a_{\sigma^{2}},b_{\sigma^{2}}+\frac{1}{2}\sum_{i=1}^{n}\sum_{j=1}^{m^{y}}(Y_{ij}-x_{ij}^{y'}\alpha_{1}+w_{ij}^{y'}u_{1i})^{2})$$

191

- 10 -

(10)

192 
$$\Theta(\alpha_{2}|U_{(-\alpha_{2})},Y_{ij}^{obs},Z_{ij}^{obs},R_{ij}^{v},R_{ij}^{z}) \propto \prod_{i=1}^{n} \prod_{j=1}^{m^{z}} \frac{\exp\left(x_{ij}^{z'}\alpha_{2} + w_{ij}^{z'}u_{2i} + Y_{j}Y_{ij}\right)^{z_{ij}}}{1 + \exp\left(x_{ij}^{z'}\alpha_{2} + w_{ij}^{z'}u_{2i} + Y_{j}Y_{ij}\right)} \times \mathbb{Z}_{p^{z}}(\alpha_{2};\mu_{\alpha_{2}},\sum_{\alpha_{2}}),$$

193

194 
$$\Theta(\Phi_1|U_{(-\Phi_1)}, Y_{ij}^{obs}, Z_{ij}^{obs}, R_{ij}^{y}, R_{ij}^{z}) \propto \prod_{i=1}^n \prod_{j=1}^{m^z} \frac{\exp\left(\psi_{ij}^{y'} \Phi_1 + \pi^{y'} u_{1i}\right)^{R_{ij}^{y}}}{1 + \exp\left(\psi_{ij}^{y'} \Phi_1 + \pi^{y'} u_{1i}\right)} \times \mathbb{D}_{p_R y}(\Phi_1; \mu_{\Phi_1}, \sum_{\Phi_1}),$$

195

199

201

196 
$$\Theta(\Phi_{2}|U_{(-\Phi_{2})},Y_{ij}^{obs},Z_{ij}^{obs},R_{ij}^{y},R_{ij}^{z}) \propto \prod_{i=1}^{n} \prod_{j=1}^{m^{z}} \frac{\exp\left(\psi_{ij}^{z'}\Phi_{2} + \pi^{z'}u_{2i} + \kappa_{j}R_{ij}^{y}\right)^{R_{ij}^{z}}}{1 + \exp\left(\psi_{ij}^{z'}\Phi_{2} + \pi^{z'}u_{2i} + \kappa_{j}R_{ij}^{y}\right)} \times \mathbb{Z}_{p_{R^{z}}}(\Phi_{2};\mu_{\Phi_{2}},\Sigma_{\Phi_{2}}),$$

198 
$$D_1 | U_{(-D_1)}, Y_{ij}^{obs}, Z_{ij}^{obs}, R_{ij}^{v}, R_{ij}^{z} \sim IWishart(\pi^v + \sum_{i=1}^n u_{1i}u'_{1i}, v + q^v + n)$$

(14)

(15)

(16)

(17)

(11)

(12)

200 
$$D_2|U_{(-D_2)}, Y_{ij}^{obs}, Z_{ij}^{obs}, R_{ij}^{\gamma}, R_{ij}^{z} \sim IWishart(\pi^z + \sum_{i=1}^n u_{2i}u'_{2i}, \nu + q^z + n)$$

202 
$$\Theta(\pi^{y}|U_{(-\pi^{y})},Y_{ij}^{obs},Z_{ij}^{obs},R_{ij}^{y},R_{ij}^{z}) \propto \prod_{i=1}^{n} \prod_{j=1}^{m^{z}} \frac{\exp\left(\psi_{ij}^{y'} \Phi_{1} + \pi^{y'} u_{1i}\right)^{R_{ij}^{y}}}{1 + \exp\left(\psi_{ij}^{y'} \Phi_{1} + \pi^{y'} u_{1i}\right)} \times \mathbb{Z}_{q_{R^{y}}}(\pi^{y};\mu_{\pi^{y}},\Sigma_{\pi^{y}}),$$

203

204 
$$\Theta(\pi^{z}|U_{(-\pi^{z})},Y_{ij}^{obs},Z_{ij}^{obs},R_{ij}^{y},R_{ij}^{z}) \propto \prod_{i=1}^{n} \prod_{j=1}^{m^{z}} \frac{\exp\left(\psi_{ij}^{z'} \Phi_{2} + \pi^{z'} u_{2i} + \kappa_{j} R_{ij}^{y}\right)^{R_{ij}^{z}}}{1 + \exp\left(\psi_{ij}^{z'} \Phi_{2} + \pi^{z'} u_{2i} + \kappa_{j} R_{ij}^{y}\right)} \times \mathbb{Z}_{q_{R^{z}}}(\pi^{z};\mu_{\pi^{z}},\Sigma_{\pi^{z}}),$$

205

206 
$$\Theta(Y_{j}|U_{(-Y_{j})},Y_{ij}^{obs},Z_{ij}^{obs},R_{ij}^{v},R_{ij}^{z}) \propto \prod_{i=1}^{n} \prod_{j=1}^{m^{z}} \frac{\exp\left(x_{ij}^{z'}\alpha_{2} + w_{ij}^{z'}u_{2i} + Y_{j}Y_{ij}\right)^{z_{ij}}}{1 + \exp\left(x_{ij}^{z'}\alpha_{2} + w_{ij}^{z'}u_{2i} + Y_{j}Y_{ij}\right)} \times \mathbb{Q}(Y_{j};\mu_{Y_{j}},\sigma_{Y_{j}}^{2}),$$

(18)

(19)

(20)

(21)

(23)

208 
$$\Theta(\kappa_{j}|U_{(-\kappa_{j})},Y_{ij}^{obs},Z_{ij}^{obs},R_{ij}^{y},R_{ij}^{z}) \propto \prod_{i=1}^{n} \prod_{j=1}^{m^{z}} \frac{\exp\left(\psi_{ij}^{z'} \Phi_{2} + \pi^{z'} u_{2i} + \kappa_{j} R_{ij}^{y}\right)^{R_{ij}^{z}}}{1 + \exp\left(\psi_{ij}^{z'} \Phi_{2} + \pi^{z'} u_{2i} + \kappa_{j} R_{ij}^{y}\right)} \times \mathbb{P}(\kappa_{j};\mu_{\kappa_{j}},\sigma_{\kappa_{j}}^{z}),$$

207

210

$$211 \qquad \Theta\left(u_{1i} \left| U_{(-u_{1i})}, Y_{ij}^{obs}, Z_{ij}^{obs}, R_{ij}^{y}, R_{ij}^{z}\right) \propto \prod_{i=1}^{m^{y}} \mathbb{E}(Y_{ij}; x_{ij}^{y'} \alpha_{1} + w_{ij}^{y'} u_{1i}, \sigma_{\varepsilon}^{2}) \times \prod_{j=1}^{m^{z}} \frac{\exp\left(\psi_{ij}^{y'} \Phi_{1} + \pi^{y'} u_{1i}\right)^{R_{ij}^{y}}}{1 + \exp\left(\psi_{ij}^{y'} \Phi_{1} + \pi^{y'} u_{1i}\right)} \times \mathbb{E}_{q^{y}}(u_{1i}; 0, D_{1}),$$

212

$$\Theta(u_{2i} | U_{(-u_{2i})}, Y_{ij}^{obs}, Z_{ij}^{obs}, R_{ij}^{v}, R_{ij}^{z}) \propto \prod_{j=1}^{m^{z}} \frac{\exp\left(x_{ij}^{z'}\alpha_{2} + w_{ij}^{z'}u_{2i} + Y_{j}Y_{ij}\right)^{z_{ij}}}{1 + \exp\left(x_{ij}^{z'}\alpha_{2} + w_{ij}^{z'}u_{2i} + Y_{j}Y_{ij}\right)} \\
\times \prod_{j=1}^{m^{z}} \frac{\exp\left(\psi_{ij}^{z'}\phi_{2} + \pi^{z'}u_{2i} + \kappa_{j}R_{ij}^{v}\right)^{R_{ij}^{z}}}{1 + \exp\left(\psi_{ij}^{z'}\phi_{2} + \pi^{z'}u_{2i} + \kappa_{j}R_{ij}^{v}\right)} \times \mathbb{Z}_{q^{z}}(u_{2i}; 0, D_{2}),$$

214

215 
$$Y_{ij}^{mis}|_{U(-Y_{ij}^{mis})}, Y_{ij}^{obs}, Z_{ij}^{obs}, R_{ij}^{v}, R_{ij}^{z} \sim N(x_{ij}^{y'}\alpha_{1} + w_{ij}^{y'}u_{1i}, \sigma_{\varepsilon}^{2})$$

217 
$$Z_{ij}^{mis}|_{\bigcup(-Z_{ij}^{mis})}, Y_{ij}^{obs}, Z_{ij}^{obs}, R_{ij}^{y}, R_{ij}^{z} \sim Ber(\lambda_{ij}).$$

218

### 219 4. Simulation studies

Some simulation studies are conducted to assess the performance of the proposed model. The first simulation is designed with assuming no association between two responses, and between measurements and missingness processes. The second simulation assumes different associations between biomarkers, also between biomarkers and missingness processes. Each simulation has 100 random samples and each sample includes 500, 1,000, and 3,000 subjects.

For each individual, the two longitudinal measurements are generated from the following joint model,

$$Y_{ij} = x_{ij}^{y'} \alpha_1 + u_{1i} + \varepsilon_{1ij}, \quad i = 1, 2, 3, ..., n, \quad j = 1, 2, 3, ..., m^y,$$
(24)

228 
$$Y_{ij}^* = x_{ij}^{z'} \alpha_2 + u_{2i} + \Upsilon_j Y_{ij} + \varepsilon_{ij}^*, \ i = 1, 2, 3, ..., n, \ j = 1, 2, 3, ..., m^z,$$
(25)

229 where  $\varepsilon_{ij}^* \sim logistic(0,1)$ ,  $Z_{ij} = 1$  for  $Y_{ij}^* \ge 0$ , and  $Z_{ij} = 0$  for  $Y_{ij}^* < 0$ .

230 For missingness processes, following models are assumed to generate data,

231 
$$R_{ij}^{\gamma}|u_{1i}\sim Ber(\lambda_{ij}^{R^{\gamma}}), \qquad (26)$$

232 where, 
$$logit(\lambda_{ij}^{R^{y}}) = \psi_{ij}^{y'} \Phi_1 + \pi^{y'} u_{1i}$$
.

$$R^{z}_{ij}|u_{2i}\sim Ber\left(\lambda^{R^{z}}_{ij}\right), \tag{27}$$

234 where, 
$$logit(\lambda_{ij}^{R^{z}}) = \psi_{ij}^{z'} \Phi_{2} + \pi^{z'} u_{2i} + \kappa_{j} R_{ij}^{y}$$
.  
235  $x_{ij}^{y'} \alpha_{1} = \alpha_{10} + \alpha_{11} t_{ij} + \alpha_{12} x_{1i} + \alpha_{13} x_{2i} + \alpha_{14} x_{3i} + \alpha_{15} x_{4i} + \alpha_{16} x_{5i} + \alpha_{17} x_{6i} + \alpha_{18} x_{7i'}$   
236  $x_{ij}^{z'} \alpha_{2} = \alpha_{20} + \alpha_{21} s_{ij} + \alpha_{22} x_{1i} + \alpha_{23} x_{2i} + \alpha_{24} x_{3i} + \alpha_{25} x_{4i} + \alpha_{26} x_{5i} + \alpha_{27} x_{6i} + \alpha_{28} x_{7i'}$   
237  $\psi_{ij}^{y'} \Phi_{1} = \Phi_{10} + \Phi_{11} X_{3i}, \quad \psi_{ij}^{z'} \Phi_{2} = \Phi_{20} + \Phi_{21} X_{4i}, \ \varepsilon_{ij} \sim N(0, \sigma_{\varepsilon}^{2}), \ u_{1i} \sim N(0, \sigma_{u_{1}}^{2}), \ u_{2i} \sim N(0, \sigma_{u_{2}}^{2}), \ t_{j} = 0, 1, 2, 3, ..., m^{z}.$ 

To make simulation feasible, each dataset included small to large individuals with longitudinal measurements. Follow-up visits are scheduled at time = {0, 1, 2, 3, 4, 5}. The true values considered for  $\alpha_1 = \alpha_2 = (1, -1, 0, 2, 1, 1, 1, -1, -1)'$  and  $\Phi_1 = \Phi_2 = (2, 1)'$ .  $x_{11}, x_{12}, x_{13}, x_{14}$  are generated from N(0,1), and  $x_{15}, x_{16}, x_{17}$  are generated from binom(n,1,0.1).  $u_i = (u_{1i}, u_{2i})$  is generated from MVN = (0,D), where

244 
$$D = \begin{pmatrix} \sigma_{11} & \sigma_{12} \\ \sigma_{21} & \sigma_{22} \end{pmatrix} = \begin{pmatrix} 1.0 & 0.5 \\ 0.5 & 1.0 \end{pmatrix}$$

245

For the SPM incorporating non-monotone, non-ignorable missing data mechanism, model (26) and model (27) are formulated following Fitzmaurice et al. [19]. We first considered independence  $(Y_{j},\kappa_{j}) = (0,0)'$ . Sample sizes are assessed by considering n = 500, n = 1,000, and n = 3,000individuals with different association parameters as  $(Y_{j},\kappa_{j}) = (1.000, -1.000)'$ ,  $(Y_{j},\kappa_{j}) =$ (0.500, -0.500)',  $(Y_{j},\kappa_{j}) = (-0.500, -0.500)'$ .

Sensitivity analysis of posterior distribution is assessed by selecting different prior distributions. 251 In the case of informative priors, the structure of prior distributions take main focus during the 252 sensitivity analysis. Non-informative priors are assessed based on changes in posterior inference. 253 All our parameters are checked for different parameters' values to assess robustness of posterior 254 means. In addition, sensitivity analysis can also be done for missingness mechanisms, where the 255 256 assessment for ignorable and non-ignorable missingness can be evaluated. We do not apply sensitivity analysis for different missingness mechanisms, as it is beyond the scope of our study 257 258 objective.

A computational procedure to estimate parameters in proposed joint model is conducted using Gibbs sampling by WinBUGS software. Two parallel MCMC sampling chains run with different starting values, convergence of chains is examined by trace plots and with diagnostic statistics suggested by Gelman et al. [18]. Posterior estimates are based on 10,000 iterations after discarding 5,000 of the burn-in period.

Data are generated under two scenarios: biomarker variability is not associated with each other (Y = 0), and both biomarkers are associated with each other ( $Y = \pm 0.5$ ,  $or \pm 1.0$ ). With that, it is also evaluated whether either missingness process is associated with the measurements process ( $\kappa = \pm 0.5$ ,  $0r \pm 1.0$ ) or not. Each dataset is then analyzed using our proposed joint model.

Based on the results presented in Table 1, it is to be noted that the performance of the proposed joint model is good. Consistency of parameter estimates is evaluated by increasing sample size which causes reduced bias and standard error for respective parameters. The same interpretation of parameter estimates holds for zero to non-zero association parameters.

272

Table 1: Results of the simulation study for binary and continuous longitudinal biomarkers data incorporating NMAR based on joint modelling for the simulation study. Estimate (Est.), standard error (SE), Bias for N = 100 simulated data with sample size 500, 1,000, and 3,000 considering association ( $Y_{ij}\kappa_i$ ) = (0.5, -0.5)'.

		n=500	)	n=1,000		n=3,000	
Parameter	Real	Est(SE)	Bias	Est(SE)	Bias	Est(SE)	Bias
α <sub>10</sub>	1.000	1.130(0.260)	0.130	0.895(0.161)	-0.105	1.088(0.101)	0.088
α <sub>11</sub>	-1.000	-1.142(0.196)	-0.142	-0.985(0.119)	0.015	-1.006(0.075)	-0.006
α <sub>12</sub>	0.000	0.275(0.118)	0.275	0.112(0.073)	0.112	-0.062(0.043)	-0.062
α <sub>13</sub>	2.000	2.587(0.397)	0.587	1.896(0.242)	-0.104	1.969(0.152)	-0.031
α <sub>14</sub>	1.000	1.066(0.209)	0.066	0.943(0.135)	-0.057	0.971(0.082)	-0.029
α <sub>15</sub>	1.000	1.093(0.215)	0.093	1.028(0.139)	0.028	1.016(0.086)	0.016
α <sub>16</sub>	1.000	1.133(0.366)	0.133	1.586(0.257)	0.586	0.962(0.151)	-0.038
α <sub>17</sub>	-1.000	-0.622(0.402)	0.378	-1.121(0.288)	-0.121	-0.991(0.162)	0.009
α <sub>18</sub>	-1.000	-1.169(0.376)	-0.169	-0.863(0.264)	0.137	-0.926(0.168)	0.074
α <sub>20</sub>	1.000	1.056(0.062)	0.056	1.050(0.043)	0.050	1.044(0.025)	0.044
α <sub>21</sub>	-1.000	-1.007(0.005)	-0.007	-0.998(0.004)	0.002	-1.000(0.002)	0.000
α <sub>22</sub>	0.000	-0.045(0.021)	-0.045	-0.033(0.030)	-0.033	-0.005(0.002)	-0.005
α <sub>23</sub>	2.000	1.976(0.039)	-0.024	1.993(0.028)	-0.007	1.999(0.015)	-0.001
α <sub>24</sub>	1.000	0.978(0.037)	-0.022	0.980(0.029)	-0.020	1.007(0.015)	0.007
α <sub>25</sub>	1.000	1.036(0.039)	0.036	1.029(0.027)	0.029	1.006(0.016)	0.006
α <sub>26</sub>	1.000	1.076(0.122)	0.076	1.069(0.092)	0.069	1.022(0.053)	0.022
α <sub>27</sub>	-1.000	-1.102(0.132)	-0.102	-1.040(0.095)	-0.040	-1.007(0.050)	-0.007
α <sub>28</sub>	-1.000	-0.765(0.120)	0.235	-1.159(0.087)	-0.159	-1.020(0.051)	-0.020
$\Phi_{10}$	2.000	1.845(0.136)	-0.155	1.992(0.101)	-0.008	1.997(0.060)	-0.003
$\Phi_{11}$	1.000	1.039(0.077)	0.039	1.030(0.058)	0.030	1.008(0.033)	0.008

$\Phi_{20}$	2.000	1.967(0.080)	-0.031	1.989(0.058)	-0.011	1.991(0.034)	-0.009
$\Phi_{21}$	1.000	0.973(0.078)	-0.027	0.990(0.056)	-0.010	0.999(0.032)	-0.001
$\sigma_{\epsilon}^2$	1.000	1.029(0.029)	0.029	1.023(0.020)	0.023	1.006(0.012)	0.006
$\sigma_{u_1}^2$	1.000	0.884(0.074)	-0.116	0.902(0.056)	-0.098	0.989(0.031)	-0.011
$\sigma_{u_2}^2$	1.000	1.562(0.556)	0.562	1.193(0.284)	0.193	1.140(0.191)	0.140
Υ <sub>1</sub>	0.500	0.341(0.189)	-0.159	0.471(0.118)	-0.029	0.495(0.075)	-0.005
Υ <sub>2</sub>	0.500	0.276(0.187)	-0.224	0.428(0.119)	-0.072	0.502(0.076)	0.002
Υ <sub>3</sub>	0.500	0.614(0.239)	0.114	0.559(0.178)	0.059	0.521(0.084)	0.021
Υ <sub>4</sub>	0.500	0.534(0.249)	0.034	0.526(0.188)	0.026	0.512(0.101)	0.012
Υ <sub>5</sub>	0.500	0.538(0.425)	0.038	0.532(0.224)	0.032	0.509(0.116)	0.009
Υ <sub>6</sub>	0.500	0.603(0.353)	0.103	0.554(0.283)	0.054	0.513(0.353)	0.013
к1	-0.500	-0.562(0.177)	-0.062	-0.556(0.134)	-0.056	-0.517(0.077)	-0.017
κ2	-0.500	-0.351(0.182)	0.149	-0.442(0.131)	0.058	-0.490(0.078)	0.010
<i>к</i> <sub>3</sub>	-0.500	-0.428(0.189)	0.072	-0.449(0.132)	0.051	-0.496(0.076)	0.004
κ4	-0.500	-0.441(0.180)	0.059	-0.450(0.133)	0.050	-0.498(0.077)	0.002
κ <sub>5</sub>	-0.500	-0.514(0.181)	-0.014	-0.510(0.132)	-0.010	-0.506(0.078)	-0.006
κ <sub>6</sub>	-0.500	-0.521(0.185)	-0.021	-0.516(0.132)	-0.016	-0.507(0.078)	-0.007
$\pi^{y}$	1.000	1.063(0.043)	0.063	0.998(0.035)	-0.002	0.998(0.029)	-0.002
$\pi^{z}$	1.000	1.183(0.711)	0.183	1.058(0.127)	0.058	1.037(0.118)	0.037

276

277

# 278 **5. Prostate cancer data analysis**

The primary objective of prostate cancer (PC) data analysis is to detect any potential association between PSA and ALP biomarkers, and to simultaneously analyze both. PC data were collected from n = 1504 patients who had at least 2 measurements of PSA, and ALP. Patients' *Age*, *Platelets*, *BMI*, *Bilirubin*, *Gleason Score*, *Grade* are recorded along with the prescribed *Drug*.

283 Following joint model is considered,

284 
$$logPSA_{ij}|u_{1i} \sim N(\mu_{ij},\sigma^2), \qquad (28)$$

$$ALP_{ik}|u_{2i} \sim Ber(\lambda_{ik}), \tag{29}$$

286

28

$$\mu_{ij} = \alpha_{10} + \alpha_{11}t_j + \alpha_{12}Age_i + \alpha_{13}Platelets_i + \alpha_{14}BMI_i + \alpha_{15}Bilirubin_i + \alpha_{16}GleasonScore_i + \alpha_{17}Drug_i + u_{1i}$$

288 and

$$logit(\lambda_{ij}) = \alpha_{20} + \alpha_{21}t_j + \alpha_{22}Age_i + \alpha_{23}Platelets_i + \alpha_{24}BMI_i + \alpha_{25}Bilirubin_i + \alpha_{26}$$

$$GleasonScore_i + \alpha_{27}Drug_i + \gamma_j logPSA_{isk} + u_{2i}$$

290

In addition, for non-ignorable missingness mechanisms following models are proposed, 291

292 
$$R_{ij}^{logPSA} \sim Ber(\lambda_{ij}^{logPSA}), \qquad (30)$$

293 where, 
$$logit(\lambda_{ij}^{logPSA}) = \Phi_{10} + \Phi_{11}Platelets_i + \Phi_{12}Bilirubin_i + \pi^{logPSA}u_{1i}$$

294 
$$R_{ik}^{ALP} \sim Ber(\lambda_{ik}^{ALP}), \qquad (31)$$

295 where, 
$$logit(\lambda_{ik}^{ALP}) = \Phi_{20} + \Phi_{21}Platelets_i + \Phi_{22}Bilirubin_i + \kappa_k R_{isk}^{logPSA} + \pi^{ALP}u_{2i}$$
,

296 
$$u_{1i} \sim N(0, \sigma_{u_1}^2)$$
, and  $u_{2i} \sim N(0, \sigma_{u_2}^2)$ 

Two parallel MCMC chains runs with different initial values for 10,000 iterations and discarded 297 first 5,000 iterations as pre-convergence burn-in. Convergence of MCMC chains is checked using 298 Gelman-Rubin diagnostic test. In addition, trace plots can plot for unknown parameters to assess 299 convergence. To get posterior inference, prior distributions for unknown parameters are selected 300 as,  $u_i = (u_{1i}, u_{2i}) \sim MVN((0,0), D_u)$ , i = 1, ..., n, where  $D_u \sim IWishart(\psi_{D_u}, v_{D_u})$ , such that the hyper-301 parameters of  $\psi_{\Sigma_u} = I_2$  and  $v_{\Sigma_u} = 2$  which lead to low-informative priors. It is also to be assumed 302 that  $\sigma_{\epsilon}^2 \sim I\Gamma(0.1,0.1)$ , the regression coefficients  $(\alpha_{i1},\alpha_{i2},\psi_{i1},\psi_{i2})'$  are fixed effects unknown 303 parameters and the prior distributions for them are N(0,1000),  $\gamma_j$ ,  $j = 1,...,m^y$  is the associated 304

parameter of the continuous longitudinal log(PSA) on the binary longitudinal ALP at time j and the prior distributions for it is N(0,1000). Prior distribution for associated parameter  $\kappa_j$ ,  $j = 1,...,m^z$ is N(0,1000),  $\pi^{logPSA}, \pi^{ALP} \sim N(0,1000)$ .

For model selection, we apply the deviance information criterion (DIC), which identifies the most suitable model by balancing between likelihood and parameters' numbers. Posterior means and the number of parameters are used in this criteria to find the best-fitted model [20].

311 
$$DIC = \overline{D}(\emptyset) + \overline{P},$$
 (32)

312 Where, 
$$\overline{P} = \overline{D}(\emptyset) - D(\overline{\emptyset})$$
, and  $D(\emptyset) = -2\log(f(\frac{w}{\theta}))$ .

313  $\overline{D}(\emptyset)$  and  $\overline{\emptyset}$  are posterior estimates of  $D(\emptyset)$  and  $\emptyset$ .  $w = w_i = (w_1, w_2, w_3, ..., w_n)$  is full data with 314 marginal density,  $f(\frac{w}{\emptyset})$  and  $\emptyset$  are vectors of model parameters. The lowest DIC leads us to the best 315 model fit, that is our proposed joint model.

The parameter estimates and their 95% posterior intervals are presented in Table 2 and summarized 316 for joint model: PSA level decreases with respect to time after treatment, and it is a good sign to 317 318 evaluate efficiency of prescribed treatment when this decrease is significant. PSA alone is not an adequate biomarker, ALP measurements are also taken into account. ALP increases with respect 319 to time for individuals, but this increase has not had any significant effect. The results indicate that 320 321 with increasing age, both PSA and ALP increase. This positive increase is significant for PSA but non-significant for ALP. Platelets are another predictor of increasing PSA significantly, but due to 322 one unit increase in platelets, ALP level decreases non-significantly with 0.026 on average. With 323 increasing BMI, patients' PSA and ALP both tend to significantly decrease. One unit increase in 324 bilirubin measurement makes a significant increase of 0.201, and 0.617 in PSA and ALP 325 measurements, respectively. The results show that PSA and ALP measurements are lower among 326 those patients with a Gleason score greater than or equal to (4+3) as compared to those whose 327

328 score is lower than and equal to (3+4), it is due to treatment effect. This study's results revealed that patients who received ALT, prostatectomy, and their combinations have lower PSA and ALP 329 measurements as compared to those who received EBRT; and this is a good sign to prove drug 330 efficacy. There exists a positive correlation between PSA and ALP measurements that can be 331 revealed with associated parameters  $\gamma$ ; while a negative association exists between missingness 332 333 and measurement processes. Results revealed that due to the existence of a positive association both PSA and ALP measurements should be simultaneously taken on PC patients to get insights 334 about PC progression. In addition, missingness must be incorporated into data to avoid loss of 335 336 information.

337

Table 2: Parameter estimates (Mean), standard deviation (Sd), and 95% CI (credible interval) of PC data, by applying
 our proposed joint SPM, and separate models.

	JIVI		Separate models		
	Mean(Sd)	95%CI	Mean(Sd)	95%CI	
	Contin	uous log(PSA)	sub-model		
α <sub>11</sub> (Intercept)	2.221(0.046)	(2.134, 2.314)	2.167(0.049)	(2.072, 2.261)	
α <sub>12</sub> (Time)	-6.597(0.080)	(-6.752,-6.437)	-6.573(0.081)	(-6.732, -6.415)	
α <sub>13</sub> (Age)	0.290(0.024)	(0.242,0.337)	0.303(0.025)	(0.254, 0.352)	
α <sub>14</sub> (Platelets)	0.251(0.036)	(0.181,0.319)	0.217(0.037)	(0.148, 0.287)	
α <sub>15</sub> (BMI)	-0.206(0.024)	(-0.253,-0.160)	-0.197(0.024)	(-0.246, -0.149)	
$\alpha_{16}$ (Bilirubin)	0.201(0.036)	(0.129,0.271)	0.193(0.037)	(0.121, 0.266)	
α <sub>17</sub> (Gleason	0.862(0.161)	(0.543,1.171)	0.862(0.179)	(0.514, 1.213)	
Score)					
α <sub>18</sub> (Drug)	0.692(0.163)	(0.384,1.009)	0.752(0.182)	(0.399, 1.108)	
$\Phi_{10}$ (Intercept)	0.475(0.029)	(0.418,0.533)	0.473(0.030)	(0.416, 0.530)	
$\boldsymbol{\Phi}_{11}$ (Platelets)	-0.003(0.001)	(-0.106,0.101)	0.005(0.003)	(-0.104, 0.101)	

$\boldsymbol{\Phi_{12}}$ (Bilirubin)	0.041(0.014)	(-0.064,0.149)	0.019(0.010)	(-0.086, 0.124)	
$\sigma_{u1}^2$	0.334(0.031)	(0.275, 0.396)	0.356(0.032)	(0.295, 0.420)	
σ²	1.399(0.034)	(1.334,1.467)	1.371(0.035)	(1.309, 1.437)	
$\pi^{logPSA}$	-0.229(0.060)	(-0.346,-0.113)	-0.229(0.062)	(-0.347,-0.113)	
	Bi	nary ALP sub-r	nodel		
α <sub>21</sub> (Intercept)	-1.741(0.335)	(-2.369,-1.076)	-0.759(0.379)	(-0.912, -0.601)	
α <sub>22</sub> (Time)	0.182(0.077)	(-1.765, 2.014)	-2.652(0.282)	(-3.236, -2.144)	
α <sub>23</sub> (Age)	0.019(0.009)	(-0.108,0.125)	0.062(0.043)	(-0.022, 0.147)	
α <sub>24</sub> (Platelets)	-0.026(0.015)	(-0.173,0.121)	-0.082(0.055)	(-0.19, 0.026)	
α <sub>25</sub> (BMI)	-0.148(0.029)	(-0.244,-0.052)	-0.135(0.039)	(-0.209, -0.058)	
α <sub>26</sub> (Bilirubin)	0.617(0.014)	(0.457,0.782)	0.487(0.047)	(0.397, 0.58)	
α <sub>27</sub> (Gleason	0.490(0.319)	(-0.230,1.095)	0.648(0.328)	(-0.033, 1.263)	
Score)					
α <sub>28</sub> (Drug)	-0.587(0.313)	(-1.138,0.048)	-0.347(0.335)	(-0.963, 0.343)	
$\Phi_{20}$ (Intercept)	1.103(0.054)	(0.997, 1.208)	1.100(0.054)	(0.990, 1.212)	
$\Phi_{21}$ (Platelets)	0.016(0.009)	(-0.100, 0.132)	0.013(0.010)	(-0.100, 0.140)	
$\boldsymbol{\Phi_{12}}$ (Bilirubin)	0.212(0.063)	(0.090, 0.337)	0.210(0.064)	(0.089, 0.340)	
$\sigma_{u2}^2$	0.104(0.033)	(0.054, 0.173)	0.101(0.035)	(0.050, 0.180)	
$\pi^{ALP}$	-0.348(0.126)	(-0.605,-0.107)	-0.343(0.129)	(-0.600, -0.112)	
Associated Parameters					
γ1	0.511(0.147)	(0.219,0.789)			
γ2	0.029(0.018)	(-0.266,0.308)			
γ <sub>3</sub>	0.217(0.150)	(-0.080,0.506)			
γ4	0.364(0.161)	(0.048,0.677)			
γ <sub>5</sub>	1.455(0.335)	(0.829,2.160)			
к <sub>1</sub>	-0.538(0.023)	(-0.585,-0.493)			
κ <sub>2</sub>	0.012(0.001)	(-0.048,0.075)			

κ <sub>3</sub>	-0.159(0.041)	(-0.239,-0.078)	
κ4	-0.382(0.070)	(-0.520,-0.243)	
κ <sub>5</sub>	-1.011(0.214)	(-1.451,-0.608)	
DIC	33308		53591

340

341

### 342 **6.** Conclusion

The primary goal of this manuscript was to jointly model different types of longitudinal outcomes 343 incorporating non-ignorable missingness. One can directly apply mixed modelling techniques with 344 considering missingness as an ignorable phenomenon. However, follow-up studies could get over 345 346 the hurdles of loss of information in case of missingness by proposing SPM for mixed-longitudinal outcomes with missingness. For each missing data process, a logit model is proposed via a latent 347 348 variable to depict the tendency of change for individuals. SPM proposed to join longitudinal and missingness models using random effects. This paper presents a joint modelling approach to 349 350 analyze longitudinal biomarkers measurements in the presence of non-ignorable missing data due to both intermittent and monotone missingness. In our PC dataset, the non-monotone missingness 351 pattern exists due to patients who missed visits, and monotone missingness data are from those 352 patients who left the follow-up and never came back to complete the treatment process. We use 353 354 logistic models to describe the missingness patterns. Our proposed model is adequate to account for the association between measurements and missingness processes, and it can be extended to 355 356 models with more than two mixed longitudinal outcomes incorporating more than two missing 357 outcomes processes.

358 Correlated random effects provide inference for non-ignorable missing data. However, the non-359 ignorable missingness assumption is untestable for the data at hand. In our collected PC dataset,

360 non-ignorable assumption is verified as missingness occurred due to lack of treatment efficacy. Therefore, we incorporated missingness process in data analysis. However, researchers must put 361 extra care to check assumptions about missingness mechanism, if the cause of missing data is not 362 internally related to responses; local sensitivity analysis should be performed. 363 This study emphasis that PC patients must be monitored for PSA and ALP simultaneously. It is 364 important to take into consideration both PSA and ALP levels as both can influence the health of 365 PC patients. In addition, missing observations must be incorporated in data analysis to get full 366 information about patients' health and wellbeing. An elevated level of PSA shows the non-367 368 effectiveness of particular treatment, and an elevated level of ALP depicts the spread of PC tumor cells. 369 370 371 Acknowledgements None. 372 373 References 374 1. Buhule OD, Wahed AS, Youk AO. Bayesian hierarchical joint modeling of repeatedly 375 376 measured continuous and ordinal markers of disease severity: Application to Ugandan diabetes data. Stat Med. 2017;36(29):4677-91. 377 2. Rubin DB. Inference and missing data. Biometrika. 1976;63:581-92. 378 3. Gao F, Miller JP, Xiong C, Beiser JA, Gordon M. The Ocular Hypertension Treatment 379 Study (OHTS) Group.: A joint-modeling approach to assess the impact of biomarker 380 variability on the risk of developing clinical outcome. Stat Methods Med. 2011;20(1):83-381 100. 382

383	4.	Alam K, Maity A, Sinha SK, Rizopoulos D, Sattar A. Joint modeling of longitudinal
384		continuous, longitudinal ordinal, and time-to-event outcomes. Lifetime Data
385		Analysis. 2021;27:64-90.
386	5.	Bahrami Samani E, Ganjali M. Bayesian latent variable model for mixed continuous and
387		ordinal responses with possibility of missing responses. J Appl Stat. 2011;38(6):1103-16.
388	6.	Dunson DB, Herring AH. Bayesian latent variable models for mixed discrete
389		outcomes. Biostatistics. 2005;6(1):11-25.
390	7.	Catalano P, Ryan LM. Bivariate latent variable models for clustered discrete and continuous
391		outcomes. J A Stat Ass. 1992;87(419):651-8.
392	8.	Leon AR, Carriere KC. On the one sample location hypothesis for mixed bivariate data.
393		Commun. Statist. Theory and Meth. 2000;29(11):2573-81.
394	9.	Liu X, Daniels MJ, Marcus B. Joint Models for the Association of Longitudinal Binary and
395		Continuous Processes With Application to a Smoking Cessation Trial. J Am Stat
396		Assoc. 2009;104(486):429-38.
397	10	Li Q, Pan J, Belcher J. Bayesian inference for joint modelling of longitudinal continuous,
398		binary and ordinal events. Stat Methods Med Res. 2016;25(6):2521-40.
399	11.	Kürüm E, Hughes J, Li R. A semivarying joint model for longitudinal binary and continuous
400		outcomes. Canadian J Stat. 2016;44(1):44-57.
401	12	Stubbendick AL, Ibrahim JG. Maximum likelihood methods for nonignorable missing
402		responses and covariates in random effects models. Biometrics. 2003;59(4):1140-50.
403	13	Hogan JW, Roy J, Korkontzelou C. Handling drop-out in longitudinal studies. Stat
404		Med. 2004;23(9):1455-97.

405	14. Gaskins JT, Daniels MJ, Marcus BH. Bayesian methods for nonignorable dropout in joint
406	models in smoking cessation studies. J Am Stat Assoc. 2016;111(516):1454-65.

- 407 15. Little RJ, Schluchter M. Maximum likelihood estimation for mixed continuous and
  408 categorical data with missing values. Biometrika. 1985;72(3):497-512.
- 409 16. Fitzmaurice GM, Laird NM. Regression models for mixed discrete and continuous
  410 responses with potentially missing values. Biometrics. 1997;53:110-22.
- 411 17. Olkin I. Tate RF. Multivariate correlation models with mixed discrete and continuous
  412 variables. Annals Math Stat. 1997;32:448-65.
- 41318. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian data analysis.
- 414 CRC Press; 2013.
- 415 19. Fitzmaurice GM, Laird NM. Ware JH. Applied Longitudinal Analysis. Wiley, Hoboken;
  416 2012.
- 20. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model
  complexity and fit. J R Stat Soc Ser B Stat Methodol. 2002;64(4):583-639.